Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02221141

Enrollment

120

Registered

2014-08-20

Start date

2013-12-31

Completion date

2021-04-30

Last updated

2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Hypertrophy

Brief summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom. Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* unexplained left ventricular hypertrophy

Exclusion criteria

* isolated septal hypertrophy

Design outcomes

Primary

Measure	Time frame
Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation	1 day

Countries

Belgium

Outcome results